GMMG-CONCEPT: Isatuximab plus KRd leads to high and sustained MRD negativity in transplant-eligible patients with high-risk NDMM Multiple Myeloma (MM) Share: Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me Forgot password? Click here
Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me
